Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial -

Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial
Information type: Randomised controlled trials
Source: Journal of the American Medical Association
Specialities: Emergency medicine and urgent care | Haematological disorders | Infection and infectious diseases
Summary
RCT of 800 patients with sepsis-associated coagulopathy found that treatment with human recombinant thrombomodulin did not significantly reduce 28-day all-cause mortality (26.8% vs 29.4%; p=0.32) and was associated with higher risk of bleeding vs placebo (5.8% vs 4.0%).
UKMi comment
A related editorial discusses the pharmacology of throbomodulin, how it differs from other anticoagulants and discusses why the trial failed to demonstrate an important difference between the groups.
Related links: Editorial